Recherche Fr menu fr ClientConnect
Recherche
Résultats
5 premiers résultats de la recherche Voir tous les résultats Recherche avancée
Recherches les plus fréquentes
Pages les plus visitées
    Référence: 20090325
    Date de publication: 15 juillet 2009

    Promoteur – Intermédiaire Financier

    A leading pharmaceutical company carrying out internationally reputable research and development activities.

    Lieu

    Description

    The project concerns the research and development activities of a major European pharmaceutical company mainly aimed at the clinical development of novel cardiology drugs addressing an existing unmet need. Additionally, it comprises the pre-clinical development of early-stage compounds, as well as efforts associated with the regulatory approval process.

    Objectifs

    The project supports the development of new drugs for the treatment of cardiovascular diseases.

    Secteur(s)

    Montant BEI envisagé (montant approximatif)

    EUR 500 million.

    Coût total (montant approximatif)

    EUR 1130 million.

    Aspects environnementaux

    R&D activities included in the project will not materially change current R&D practice and will be carried out within existing facilities, making use of existing laboratories, pilot plants, clinical centres, etc. An EIA, therefore, is not required by EU Directive 97/11 amended by Directive 2003/35. By the very nature of activities involved and the location of the sites, impact on the biodiversity of terrestrial, freshwater and marine environments will be negligible.

    Passation des marchés

    The promoter is a private company not operating in the Utilities sector, and is thus not covered by EU Directives on procurement. The project will be mostly implemented by experienced staff within in the promoter’s existing R&D organization, in co-operation with university hospitals and specialised contract service providers. The promoter has sound procedures for procuring specialised equipment and external services. These procedures are in the best interest of the project and satisfactory to the Bank.

    Statut

    Signé - 24/06/2010

    Clause de non-responsabilité

    Avant d’être approuvés par le Conseil d’administration et avant la signature des prêts correspondants, les projets font l’objet d’une instruction et de négociations. Par conséquent, les informations et données fournies sur cette page sont indicatives.
    Elles sont fournies à des fins de transparence uniquement et ne peuvent être considérées comme représentant la politique officielle de la BEI (voir également les notes explicatives).

    Mots-clés correspondants

    Allemagne Industrie